Latest news with #AtopicDermatitis
Yahoo
22-05-2025
- Health
- Yahoo
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis to 2033
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: 68-Market Drug Forecast and Market Analysis" report has been added to publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for atopic dermatitis, covered in the analyst's report "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis", published in March 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare and POLI Price Intelligence databases. For more information on the methodology and assumptions used in the analyst's forecast extrapolations, please refer to the Methodology and Assumptions tabs in the Excel model for this analyst estimated that the atopic dermatitis market was $12.0 billion across the 68MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $28.6 billion, increasing at a compound annual growth rate (CAGR) of 9.1%. This strong growth will be fuelled by driven by the launch of 17 late-stage pipeline agents in the 7MM, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast Overview of AD - including epidemiology, disease etiology and management.? Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs in the 7MM.? Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.? Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.? Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.? Develop business strategies by understanding the trends shaping and driving the atopic dermatitis (AD) therapeutics market.? Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.? Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.? Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.? Track drug sales in the seven-market AD therapeutics market from 2023-2033.? Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.? Key Topics Covered: 1 Executive Summary1.1 Overview1.2 68M summary statistics1.3 Key 7MM events driving the 68M forecast extrapolation2 Appendix2.1 Abbreviations2.2 Methodology2.2.1 Patient-based forecast methodology2.2.2 68M forecast extrapolation methodology2.3 Primary research - key opinion leaders interviewed for this report2.4 Primary research - prescriber survey2.5 About the authors2.5.1 Analyst2.5.2 Managing analyst2.5.3 Therapy area directors2.5.4 Epidemiologist2.5.5 Epidemiology reviewers2.5.6 Vice President of Disease Intelligence and Epidemiology2.5.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence3 About the AnalystCompanies Featured AbbVie Aclaris Therapeutics Acrotech Biopharma Amgen AOBiome Therapeutics Arcutis Biotherapeutics Astria Therapeutics Dermavant Eli Lilly Galderma GlaxoSmithKline Incyte Japan Tobacco Kyowa Kirin LEO Pharma Maruho Nektar Otsuka Pfizer Regeneron Sanofi Torii Pharmaceutical Union Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2025
This comprehensive report offers an overview of clinical trials, featuring data by region, country, phase, and sponsor type. Unlock competitive advantages with detailed analysis of ongoing trials and enrollment trends. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to offering. The report delivers a comprehensive insight into the current landscape of clinical trials focused on Atopic Dermatitis (Atopic Eczema) worldwide. Leveraging data from the proprietary Pharma - Clinical trials database, the report encapsulates a broad spectrum of clinical trial information, presenting crucial statistics such as trial numbers and average enrollment across leading countries globally. This robust database aggregates information from over 80 diverse sources including clinical trial registries, conferences, journals, and news outlets, ensuring a meticulously updated repository of data. The report's extensive coverage includes detailed insights broken down by region and country (G7 & E7), trial phase, trial status, endpoints, and sponsor type. It highlights active trials and the significant drugs that are currently under investigation, aligning strategic interests with ongoing developments in the field of Atopic Dermatitis (Atopic Eczema). Benefits of engaging with this report extend to enhancing decision-making capabilities, crafting strategic responses, and securing a competitive market advantage. Although some sections may be adapted based on data availability and relevance, the offering continues to provide an indispensable tool for stakeholders aiming to navigate the clinical trials landscape effectively. Scope: Presents a snapshot of the global clinical trials environment. Delivers top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. Evaluates leading companies and lists trials (title, phase, and status) associated with them. Documents all unaccomplished trials (terminated, suspended, and withdrawn), including reasons for their cessation. Analyzes enrollment trends over the past five years. Reports on the latest relevant news from the last three months. Key Topics Covered: Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by E7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Clinical Trials by Sponsor Type Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema) Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Pfizer Inc Novartis AG Sanofi Regeneron Pharmaceuticals Inc LEO Foundation Eli Lilly and Co AbbVie Inc Johnson & Johnson Innovaderm Research Inc Thermo Fisher Scientific Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Time of India
02-05-2025
- Health
- Time of India
New study finds tofacitinib effective and affordable for refractory atopic dermatitis
New Delhi: New Delhi: Tofacitinib , a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address moderate to severe cases of rheumatoid arthritis and ankylosing spondylitis, demonstrates effectiveness in managing refractory atopic dermatitis (AD). Tired of too many ads? go ad free now This was revealed in a study published in the Indian Dermatology online journal. Atopic dermatitis (AD) presents as a long-term, recurring inflammatory disorder of the skin, and its characteristic itching significantly affects patients' daily living standards. The research was conducted at the department of dermatology, venereology and leprosy in Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital. The results established that people who previously showed no response to standard systemic treatments, including oral corticosteroids, cyclosporine and azathioprine, exhibited significant clinical improvement when administered tofacitinib exclusively. The progress was evaluated through decreased Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Numerical Rating Scale (NRS) measurements at 4-week and 8-week intervals. The principal investigator of the study and dermatologist at RML Hospital, professor Kabir Sardana, explained that their main goal was to evaluate how well tofacitinib worked and its side effects in patients with difficult-to-treat moderate-to-severe AD. Additionally, they aimed to analyse the treatment costs between tofacitinib and dupilumab (approved by the Central Drugs Standard Control Organisation, India) for moderate and severe AD cases. Tired of too many ads? go ad free now The research indicated an average disease duration of three years. Patients displayed moderate to severe pruritus, excoriations, erythema, oozing and crusting. All participants had previously experienced treatment failure or intolerance to systemic therapy; 50% of patients also had other atopic conditions and bronchial asthma. The researchers continued treatment with topical corticosteroids, moisturiser and topical calcineurin inhibitors alongside tofacitinib. Improvements were observed in pruritus, sleep quality, affected body surface area, erythema, excoriation, papulation/edema and lichenification, with notable severity score reductions at four weeks and eight weeks of therapy. Dr Sardana said that EASI 90 was attained by 66% of patients within 8 weeks, with one patient experiencing treatment failure. Patients achieved complete or near-complete disease resolution in an average of 6.1 weeks (ranging from 3-8 weeks). Disease recurrence was observed in 36.3% of patients. Adverse reactions occurred in 41.6% of patients, including herpes zoster, dyslipidemia, anaemia, impetigo, and thrombocytosis. The financial comparison revealed that dupilumab (a monoclonal antibody used to treat various allergic conditions, including atopic dermatitis, asthma, and nasal polyps) therapy costs 122 times more than tofacitinib treatment over an 8-week period.
Yahoo
04-03-2025
- Business
- Yahoo
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology. As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials. Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need." Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024." André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards." About MEndoB Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology. About Micreos Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond. For more information, visit About Northway Biotech Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA. For more information, please visit Micreos Contact: Matt ReganCEO and Board member, Micreos Pharmaceutical Northway Biotech Contact: Vladas Algirdas BumelisCEO and Chairman of the Contact Information Vladas Bumelis CEO and Chairman of the SOURCE: Northway Biotech View the original press release on ACCESS Newswire
